Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is undervalued on P/FCF.
Buy
Sell